olanzapine is effective in patients with borderline personality disorder and comorbid dysthymia,

Inpharma 1219 - 8 Jan 2000

■ Olanzapine is effective in patients with borderlinepersonality disorder and comorbid dysthymia, reportUS-based researchers. In this 8-week open-label pilotstudy, low-dose olanzapine (final average dosage of7.73 mg/day) produced significant reductions frombaseline in the total scores of self- and clinician-ratedscales in 11 such patients.* ;† In addition, globalassessment of function improved by 29%. Patients didnot experience movement disorder adverse effectsduring olanzapine therapy.* This study was supported by Eli Lilly and Company.† The scales used included the Hopkins Symptom Checklist 90, theBrief Psychiatric Rating Scale, the modified Schedule forInterviewing Borderlines, the Buss-Durkee Hostility Inventory andthe Barratt Impulsivity Scale.

Schulz SC, et al. Olanzapine safety and efficacy in patients with borderlinepersonality disorder and comorbid dysthymia. Biological Psychiatry 46:1429-1435, 15 Nov 1999 800808194

1

Inpharma 8 Jan 2000 No. 12191173-8324/10/1219-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved